Back to School: How biopharma can reboot drug development. Access exclusive analysis here

deCode plans up to $200 million NASDAQ IPO

deCode Genetics (Reykjavik, Iceland), a population

Read the full 60 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE